AstraZeneca (LON:AZN) Raised to “Hold” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca (LON:AZN) to a hold rating in a research note published on Monday, MarketBeat reports.

AZN has been the topic of several other reports. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a report on Thursday, April 4th. BMO Capital Markets reaffirmed an outperform rating on shares of AstraZeneca in a research report on Monday, February 12th. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research report on Monday. Barclays reaffirmed an overweight rating and issued a £125 ($155.61) price target on shares of AstraZeneca in a research report on Monday, April 8th. Finally, Berenberg Bank reissued a buy rating on shares of AstraZeneca in a research report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of £115.43 ($143.69).

AstraZeneca Price Performance

Shares of LON:AZN opened at £108.62 ($135.22) on Monday. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70. AstraZeneca has a 1 year low of GBX 9,461 ($117.78) and a 1 year high of £123.92 ($154.26). The business has a fifty day simple moving average of £103.49 and a 200 day simple moving average of £104.25. The firm has a market cap of £168.36 billion, a price-to-earnings ratio of 3,584.82, a P/E/G ratio of 0.89 and a beta of 0.19.

AstraZeneca Increases Dividend

The business also recently disclosed a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were issued a dividend of GBX 156 ($1.94) per share. This represents a yield of 1.49%. This is an increase from AstraZeneca’s previous dividend of $71.80. The ex-dividend date was Thursday, February 22nd. AstraZeneca’s payout ratio is presently 7,524.75%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.